Managing Infection Risk and Safety Monitoring with Anti-CD20 MS Disease Modifying Therapy

In this episode titled "Managing Infection Risk and Safety Monitoring with Anti-CD20 MS Disease Modifying Therapy," Dr. Williams raises the issue of infection risk — a topic of increasing clinical relevance.

Dr. Krieger frames the key principle: the longer a patient is on B-cell depletion, the more infection risk may gradually creep upward. He communicates this to patients at the time of initiation by framing therapy as a "5-to-10-year plan" — not because it is inherently time-limited, but because monitoring practices, risk stratification tools, and extended-interval dosing strategies will mature over that period. Specific infections to consider include pneumonia, meningitis, and disseminated zoster. Inflammatory colitis have also emerged as complications warranting vigilance.

Dr. Bove describes her monitoring protocol: pre-treatment vaccination review (including HPV), periodic clinical assessment (asking about UTIs, colds, sinusitis relative to household norms), and laboratory monitoring at least annually for CBC differential (including T cells and neutrophils), IgG, and TB exposure. She introduces the "smartphone test" — observing whether patients at follow-up visits are sharing photos of their lives or discussing infections — as an informal gauge of infection burden.

On breast cancer screening (initially flagged in the ocrelizumab label), the panel notes no epidemiologically significant increase has been observed over the decade of B-cell depletion use, though routine cancer screenings remain important for all patients.

In the next episode, "Hypogammaglobulinemia in MS Patients on Anti-CD20 Therapy: When to Act," the panel examines IgG monitoring, risk stratification, and thresholds for clinical intervention.